DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device ...

Earlier on November 25, Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. While ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other ...

San Diego-based Dexcom, a maker of continuous glucose monitors, has filed for a patent for a system that would integrate a smartphone with a Dexcom device, detailing some of the features such a device ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510 (k) clearance from the FDA. The system is designed ...

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 ...

A seasoned news and features author, Aakash operates at the intersection of tech, business, and marketing. Previously, he was an Editor at TechRadar and Mashable, before moving to Product Marketing ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...